Search

Displaying results 1691 - 1700 of 2674 in total
  1. Drug

    Octasulfur

    go.drugbank.com/drugs/DB09353
    Approved

    Sulfur is a chemical element that is present in all living tissues. The most commonly used form of pharmaceutical sulfur is Octasulfur (S8). After calcium and phosphorus, it is the third most abundant mineral in the human body. Sulfur is...

    Mixtures: Prascion RA, Prascion RA Cream with Sunscreens
  2. Drug

    Clodronic acid

    go.drugbank.com/drugs/DB00720
    ApprovedInvestigationalVet approved

    [A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910]

  3. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    [L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

  4. Drug

    Metamfetamine

    go.drugbank.com/drugs/DB01577
    ApprovedIllicitInvestigationalWithdrawn

    The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.[L43942]

    Categories: Adrenergic alpha-2 Receptor Agonists
  5. Drug

    Chloroform

    go.drugbank.com/drugs/DB11387
    ApprovedVet approvedWithdrawn

    Chloroform is part of the FDA drug products withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]

  6. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

  7. Drug

    Dichlorobenzyl alcohol

    go.drugbank.com/drugs/DB13269
    Approved

    [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]

  8. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.

  9. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.

  10. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Therefore, the FDA has withdrawn nylidrin from the U.S. market [L2286]. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.